Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)

NCT01303237 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01303237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Observational
Overall status
Terminated
Start date
February 28, 2011
Completion date
August 5, 2014
Enrollment
88 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

la scchn, unresectable locally advanced squamous cell carcinoma of head and neck